10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2015 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 26, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 4,459 | 11,934 | 4,517 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 6,375 | 6,691 | 6,988 |
| Intangible asset impairment charges | 162 | 1,222 | 765 |
| Foreign currency devaluation related to Venezuela | 876 | 0 | 140 |
| Net charge related to the settlement of Vioxx shareholder class action litigation | 680 | 0 | 0 |
| Gain on divestiture of Merck Consumer Care business | 0 | (11,209) | 0 |
| Gain on AstraZeneca option exercise | 0 | (741) | 0 |
| Loss on extinguishment of debt | 0 | 628 | 0 |
| Equity income from affiliates | (205) | (257) | (404) |
| Dividends and distributions from equity method affiliates | 50 | 185 | 237 |
| Deferred income taxes | (764) | (2,600) | (330) |
| Share-based compensation | 299 | 278 | 276 |
| Other | 757 | (95) | 259 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (480) | (554) | 436 |
| Inventories | 805 | 79 | (365) |
| Trade accounts payable | (37) | 593 | 522 |
| Accrued and other current liabilities | (8) | 1,635 | (397) |
| Income taxes payable | (266) | (21) | (1,421) |
| Noncurrent liabilities | (277) | 190 | (132) |
| Other | (5) | (98) | 563 |
| Net Cash Provided by Operating Activities | 12,421 | 7,860 | 11,654 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,283) | (1,317) | (1,548) |
| Purchases of securities and other investments | (16,681) | (24,944) | (17,991) |
| Proceeds from sales of securities and other investments | 20,413 | 15,114 | 16,298 |
| Divestiture of Merck Consumer Care business, net of cash divested | 0 | 13,951 | 0 |
| Dispositions of other businesses, net of cash divested | 316 | 1,169 | 46 |
| Proceeds from AstraZeneca option exercise | 0 | 419 | 0 |
| Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired | (7,598) | 0 | 0 |
| Acquisition of Idenix Pharmaceuticals, Inc., net of cash acquired | 0 | (3,700) | 0 |
| Acquisitions of other businesses, net of cash acquired | (146) | (181) | (246) |
| Acquisition of Bayer AG collaboration rights | 0 | (1,000) | 0 |
| Cash inflows from net investment hedges | 139 | 195 | 350 |
| Other | 82 | (80) | (57) |
| Net Cash Used in Investing Activities | (4,758) | (374) | (3,148) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | (1,540) | (460) | (159) |
| Payments on debt | (2,906) | (6,617) | (1,775) |
| Proceeds from issuance of debt | 7,938 | 3,146 | 6,467 |
| Purchases of treasury stock | (4,186) | (7,703) | (6,516) |
| Dividends paid to stockholders | (5,117) | (5,170) | (5,157) |
| Other dividends paid | 0 | (77) | (120) |
| Proceeds from exercise of stock options | 485 | 1,560 | 1,210 |
| Other | 56 | 208 | 60 |
| Net Cash Used in Financing Activities | (5,270) | (15,113) | (5,990) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (1,310) | (553) | (346) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 1,083 | (8,180) | 2,170 |
| Cash and Cash Equivalents at Beginning of Year | 7,441 | 15,621 | |
| Cash and Cash Equivalents at End of Year | 8,524 | 7,441 | 15,621 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |